Showing results (291-300 of 317) with videos related to
Sort By:
Pageof 32
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 8, 2019
Aurora Kinase A Inhibition Provides Clinical Benefit, Normalizes Megakaryocytes, and Reduces Bone Marrow Fibrosis in Patients with Myelofibrosis: A Phase I TrialNaseema Gangat, Christian Marinaccio, Ronan Swords, et al.Nature Communications|May 19, 2021
RAS mutations drive proliferative chronic myelomonocytic leukemia via a KMT2A-PLK1 axisRyan M Carr, Denis Vorobyev, Terra Lasho, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 18, 2017
Prospective, Randomized, Double-Blind, Phase III Clinical Trial of Anti-T-Lymphocyte Globulin to Assess Impact on Chronic Graft-Versus-Host Disease-Free Survival in Patients Undergoing HLA-Matched Unrelated Myeloablative Hematopoietic Cell TransplantationRobert J Soiffer, Haesook T Kim, Joseph McGuirk, et al.The Lancet. Digital Health|July 14, 2022
Development of a multiomics model for identification of predictive biomarkers for COVID-19 severity: a retrospective cohort studySeul Kee Byeon, Anil K Madugundu, Kishore Garapati, et al.Blood Advances|July 11, 2025
Landscape and clinicopathologic features of RAS pathway mutations in chronic myelomonocytic leukemiaGuillermo Montalban-Bravo, Sanam Loghavi, Ziyi Li, et al.Blood|April 21, 2023
Spectrum of clonal hematopoiesis in VEXAS syndromeFernanda Gutierrez-Rodrigues, Yael Kusne, Jenna Fernandez, et al.The Lancet. Oncology|October 3, 2024
Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trialEunice S Wang, Ghayas C Issa, Harry P Erba, et al.Blood|May 7, 2025
BLAST: A Globally Applicable and Molecularly Versatile Survival Model for Chronic Myelomonocytic LeukemiaAyalew Tefferi, Saubia Fathima, Maymona Abdelmagid, et al.American Journal of Hematology|December 13, 2024
Mayo Genetic Risk Models for Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax + Hypomethylating AgentNaseema Gangat, Azeem Elbeih, Nour Ghosoun, et al.Blood Advances|March 14, 2025
Evidence-based risk stratification of myeloid neoplasms harboring TP53 mutationsMithun Vinod Shah, Kevin Hung, Anmol Baranwal, et al.Pageof 32